Search Results
Aug 25, 2026, 09:15 ET /C O R R E C T I O N -- Akeso, Inc./
platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.Backed by world-class GMP manufacturing facilities and a highly efficient, integrated
More news about: Akeso, Inc.
Aug 24, 2026, 03:01 ET ImmunoForge Selected for the Ministry of SMEs and Startups' 'Global TIPS R&D' Program… "Expansion of the LMT Platform"
collaborative research and co-development to identify CNS-targeted drug candidates by utilizing LNP technologies with various modalities, including mRNA, siRNA, and ASO. We are already receiving interest from global companies and are currently discussing collaborative research with multiple companies.""We
More news about: ImmunoForge Co., Ltd.
Aug 21, 2026, 05:28 ET China's Personalized mRNA Cancer Therapy Sector Accelerates: How Far Is It From a "DeepSeek Moment"?
field, Beijing-based Likang Life Sciences is among the more clinically advanced developers in China's personalized mRNA cancer vaccine sector.Clinical Development of Personalized mRNA Cancer Vaccines Accelerates in ChinaIn 2023, LK101, developed by Likang Life Sciences, received clinical
More news about: Likang Life Sciences
Aug 20, 2026, 19:10 ET Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results
BRII-5395, an internally discovered mRNA therapeutic vaccine for advanced hepatocellular carcinoma (HCC). This milestone represents the first clinical evaluation of an RNA-based therapeutic originating from Brii Bio's internal discovery efforts. While BRII-5395 is an mRNA therapeutic vaccine, the Company's
More news about: Brii Biosciences Limited
Aug 13, 2026, 18:16 ET Innorna für den „Prix Galien USA Best Startup Award" 2026 nominiert
engere Auswahl aufgenommen, was die Innovationskraft seiner mRNA-LNP-Plattform sowie eine klinische Pipeline widerspiegelt, die über Impfstoffe hinaus bis hin zu Therapeutika reicht. Das Leitprogramm des Unternehmens, IN026, ist eine neuartige mRNA-Therapie zur Behandlung von therapieresistenter Gicht, die
More news about: Innorna Co., Ltd.
Aug 13, 2026, 10:00 ET Innorna Nominated for 2026 Prix Galien USA Best Startup Award
innovation in its mRNA-LNP platform and a clinical pipeline that has advanced beyond vaccines into therapeutics. The company's lead program, IN026, is a novel mRNA therapy for refractory gout, designed to reduce uric acid. It received FDA IND clearance in March 2026, extending mRNA-based protein replacement
More news about: Innorna Co., Ltd.
Aug 13, 2026, 10:00 ET Innorna Nominated for 2026 Prix Galien USA Best Startup Award
innovation in its mRNA-LNP platform and a clinical pipeline that has advanced beyond vaccines into therapeutics. The company's lead program, IN026, is a novel mRNA therapy for refractory gout, designed to reduce uric acid. It received FDA IND clearance in March 2026, extending mRNA-based protein replacement
More news about: Innorna Co., Ltd.
Aug 12, 2026, 08:17 ET Ivonescimab Plus Chemotherapy Approved for First-Line Squamous NSCLC; HARMONi-6 Establishes New Gold Standard in Lung Cancer Treatment
platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.Backed by world-class GMP manufacturing facilities and a highly efficient, integrated
More news about: Akeso, Inc.
Aug 12, 2026, 07:00 ET Leap Therapeutics Announces Publication of DeFianCe Study Results in Clinical Cancer Research
orthogonal platforms — an aptamer-based SomaScan assay and an antibody-based Meso Scale Discovery (MSD) assay (Spearman r=0.77).Tumoral DKK1 mRNA expression was low in most tissue samples, reinforcing that plasma — not tissue — reflects the systemic DKK1 burden relevant to colorectal cancer biology,
More news about: Cypherpunk Technologies Inc.
Aug 11, 2026, 10:30 ET Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia
demonstrated a favorable safety and tolerability profile.Preclinical and clinical studies have also demonstrated that GV101 increases both frataxin mRNA and protein levels in patient-derived B-lymphocytes and fibroblasts. Consistent with these findings, oral ROCK2 inhibition with GV101 increased frataxin
More news about: Graviton Bioscience Corporation
Aug 11, 2026, 08:58 ET Stand Up To Cancer Nicolai Award Will Fund KRAS-Targeted Immunotherapy Combination for Pancreatic Cancer
bring to the project their expertise and experience in developing mRNA vaccines. Funding from the award will support their efforts to engineer an mRNA vaccine with a specialized Cap2 structure, a chemical feature at the front end of mRNA, that is designed to help maintain antigen production and, thus,
More news about: Stand Up To Cancer, a division of the Entertainment Industry Foundation
Aug 10, 2026, 05:27 ET Dx&Vx Signs Two Material Transfer Agreements in Latin America Within Two Months -- "Technology Validated Across Both Public and Private Sectors"
under a name reflecting "Kinetic RNA". The platform applies to a wide range of nucleic acid-based modalities, including mRNA vaccines, RNA-based therapeutics, DNA vaccines, aptamers, gene therapies, and gene-editing tools. Once material transfer is complete, partners conduct
More news about: Dx&Vx
Aug 10, 2026, 00:05 ET Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer
platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.Backed by world-class GMP manufacturing facilities and a highly efficient, integrated
More news about: Akeso, Inc.
Aug 06, 2026, 07:30 ET Ractigen Therapeutics Announces Completion of Enrollment and First Dosing in Phase II Clinical Trial of RAG-17 for SOD1-ALS
designed using Ractigen's proprietary SCAD™ delivery platform technology to specifically target and silence the superoxide dismutase 1 (SOD1) gene mRNA. Mutations in the SOD1 gene cause a toxic gain-of-function and are a known cause of familial ALS. By reducing the production of the toxic mutant SOD1
More news about: Ractigen Therapeutics
Aug 05, 2026, 08:00 ET Porton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services to Commercialization
spectrum of CGT products, including plasmids, lentivirus, cell therapies (CAR-T, TCR-T, UCAR-T, NK, CAR-NK, MSC, TIL, iPSC, etc.), in vivo CAR-T, mRNA, and exosomes. This supports clients across the entire CGT product lifecycle, from IND filing and clinical research through to commercialization, effectively
More news about: Porton Advanced
Aug 05, 2026, 07:31 ET Porton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services to Commercialization
modification.Porton Advanced provides CDMO services for CGT products, including plasmids, lentivirus, cell therapies, in vivo CAR-T, mRNA, and exosomes. Currently, we are supporting a cell therapy project that is nearing a BLA submission. The acquisition of the Drug Manufacturing License
More news about: Porton Advanced
Aug 05, 2026, 05:34 ET Everest Medicines to Announce 2026 Interim Results and Host Online Investor Call on August 19, 2026
omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster
More news about: Everest Medicines
Jul 31, 2026, 07:00 ET CREATE Medicines Expands Targeted In Vivo CAR Platform Through Strategic Research Collaboration and Exclusive License Agreement with Monash University
downstream milestone and royalty payments."Monash brings world-class LNP engineering and paired with our already clinically validated and targeted mRNA platform, we can further apply that precision across an even broader range of targets," said Daniel Getts, PhD, Founder and Chief Executive Officer
More news about: CREATE Medicines, Inc.
Jul 31, 2026, 02:15 ET CellOrigin Unveils Two Novel Solid-Tumor Cell Therapy Candidates at ASCO 2026, Partners with Walvax for In Vivo CAR Clinical Trial
2026. The initial findings indicate a generally well-tolerated safety profile and promising signs of clinical activity. The second, TMT Engager™, an LNP-mRNA-based in vivo T-cell engager, enables in situ formation of T-cell–macrophage–tumor cell tripartite conjugates, a strategy designed to engage both innate
More news about: CellOrigin
Jul 30, 2026, 08:33 ET Seoul National University of Science and Technology Researchers Show Perilla Oil Improves Blood Circulation and Coagulation in Healthy Smokers
analysis showed that perilla oil significantly prolonged collagen-induced ADP closure time (C-ADP CT), indicating improved platelet function, and reduced mRNA expression of inflammatory markers TNF-α and TBX21. It also increased levels of ALA, its metabolites, and eicosapentaenoic acid (EPA) in plasma and
More news about: Seoul National University of Science and Technology
Jul 30, 2026, 07:00 ET CREATE Medicines Receives Approval to Initiate First-in-Human Phase 1/2 Clinical Trial of In Vivo CAR-T Candidate CRT-402 for Autoimmune Diseases
CREATE Medicines' lead in vivo CAR-T candidate in autoimmune disease, a CD19-targeted in vivo CAR-T therapy delivered using the company's proprietary mRNA-LNP platform. The therapy is designed to enable deep B cell depletion and immune reset while offering the potential advantages of repeat dosing and
More news about: CREATE Medicines, Inc.
Jul 28, 2026, 10:30 ET Biopharmaceutical Process Analytical Technology Market worth $4.32 billion by 2031 - Exclusive Report by MarketsandMarkets™
optimize production yields, and comply with stringent regulatory standards. The growing development of next-generation vaccine platforms, including mRNA, viral vector, recombinant protein, and nanoparticle-based vaccines, is increasing the need for advanced analytical technologies to support complex manufacturing
More news about: MarketsandMarkets
Jul 27, 2026, 22:35 ET Akeso IO2.0 + ADC2.0 Strategy Makes Another Advancement: First Patient Dosed in Phase Ib/II Study of HER3 ADC (AK138D1) Combined with Ivonescimab in Lung Cancer
platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.Backed by world-class GMP manufacturing facilities and a highly efficient, integrated
More news about: Akeso, Inc.
Jul 27, 2026, 11:14 ET Everest Medicines Announces Participation in Upcoming Investor Conferences
omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster
More news about: Everest Medicines
Jul 23, 2026, 03:00 ET ARTHEx Biotech Publishes First Demonstration of Improvement in a DM1-related Behavioral Alteration in a Preclinical Model of Myotonic Dystrophy Type 1 (DM1)
activity occurs through two complementary mechanisms: first, upregulation of miR-23b reduces MBNL protein expression; and second, expanded toxic DMPK mRNA sequesters MBNL proteins within the nucleus. The resulting depletion of available MBNL proteins leads to widespread RNA mis-splicing (spliceopathy),
More news about: ARTHEx Biotech